|
|
|
Real Estate News Releases
|
(EstateNewsWire.com, July 1, 2012 ) New York, NY -- VFC's Stock House, an information and research outlet that brings ideas and opens discussions to a broad spectrum of investors, has identified shares of Lpath Inc (LPTN) as potentially undervalued and gearing to move higher.
For full report visit: http://vfcsstockhouse.com/blog/article/-lpath-shares-may-be-undervalued-with-key-catalysts-in-play
Shares of Lpath, Inc. were cruising along earlier this year at prices over the dollar mark and supported by volume fluid enough to sustain those levels. Investors were keyed into this small company's status as a recognized leader in the field of lipid-based therapeutics and were also quick to notice the interest of Pfizer, Inc (PFE), which jumped on board early on in development when it became apparent that Lpath was, at least to date, the only company to have successfully developed monoclonal antibodies against bioactive lipids.
The targeting of bioactive signaling lipids has been the subject of increased medical research over recent years and Lpath, with its ImmuneY2 platform, is the only company to yet take the technology as far along in development as it has.
Lpath's ImmuneY2 platform contains the ability to generate therapeutic antibodies that bind to and inhibit bioactive lipids that contribute to the spreading and growth of various diseases and inflammatory/auto-immune disorders. The market potential for this technology in treating a plethora of modern day illnesses and diseases, should it advance past the clinical stages, is huge, and Lpath is first applying its technology to the treatment of Wet AMD and cancer, both multi-billion dollar markets, and that could just be the beginning.
As key catalysts play out later this year, it's likely that shares of LPTN could quickly return to at least the dollar mark.
Contact VFC's Stock House: vfc@vfcsstockhouse.com
Originally published at: http://vfcsstockhouse.com
Follow VFC's Stock House on Twitter: https://twitter.com/#!/VFCsStockHouse
'Like' VFC's Stock House on Facebook: http://www.facebook.com/pages/VFCs-Stock-House/143724412345213
About VFCsStockHouse.com:
VFC's Stock House is an information and research outlet that brings new ideas to the table and opens discussions for a broad spectrum of investors, with a strong focus on - but not limited to - biotech stocks, biopharma stocks, growth stocks and the pharmaceutical and healthcare sectors. VFC's Stock House provides individual company profiles, write-ups and reports as well as giving general insights into broader-market news through various 'Stock Watch' lists. At the conclusion of most weeks, VFC's Stock House issues a "Weekly Stock Watch" that examines news items, stocks and stories that made headlines during the previous trading week, but may also make headlines or influence trends during the upcoming week as well. The information contained within the pages of VFC’s Stock House are not intended to be taken as advice, but as a starting point where investors can follow up with their own DD and devise their own entry and exit strategies.
For full disclaimer visit: http://vfcsstockhouse.com
VFC's Stock House
VFC
240-786-2111
vfc@vfcsstockhouse.com
Source: EmailWire.Com 
|
|
|
|
Real Estate News by Sector
|
|
|
|
|
